BMS-135-L-Lys
BMS-135-L-Lys is a dual-cation prodrug derived from CK2 inhibitor BMS-135 (HY-181022) through esterification with L-lysine using a secondary alcohol. BMS-135-L-Lys achieves enhanced solubility by maintaining protonation of the ε-amino group of the Lys side chain at intestinal pH. BMS-135-L-Lys is released in situ by intestinal wall esterase from the parent drug, significantly increasing the oral bioavailability of the parent drug and overcoming the non-linear pharmacokinetic problem when the dose of the parent drug is increased. BMS-135-L-Lys can be used in related research on colon cancer and lung cancer.
For research use only. We do not sell to patients.
- Formula: C28H35ClN12O4
- Molecular Weight:639.11
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Molecular Weight 639.11
-
Formula C28H35ClN12O4
-
SMILES
N#CC1=CN=C2N1N=C(N=C2NCC)NC3=C(C(N4C[C@H]([C@@H](CC4)NC(OC)=O)OC([C@H](CCCCN)N)=O)=CC(C#N)=C3)Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Subbaiah MAM, et al. Drug Delivery Strategy Exploiting Amino Acid Prodrugs: Improving Oral Bioavailability and Overcoming Nonlinear Pharmacokinetic Challenges Following Dose Escalation of a CK2 Inhibitor with Poor Solubility. Journal of medicinal chemistry. 2026 Jun 25;69(12):14836-14853. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)